A Doubling of Cardiovascular Risk
Recent research provides a stark warning for patients who discontinue GLP-1 medications. An observational study involving over 80,000 people with Type 2 diabetes in Italy found that stopping treatment was associated with approximately double the risk
of a major cardiovascular event—such as a non-fatal heart attack or stroke—or death from any cause, compared to those who continued the therapy. The rate of these serious events was 3.94 per 100 person-years in those who stopped, versus 1.96 in those who remained on the medication. Another large study of U.S. veterans found that being off the treatment for two years was linked to a 22% higher risk of heart attack, stroke, and death.
The Rebound Effect Explained
The increased risk is not just a statistical anomaly; it is rooted in biology. GLP-1 drugs work by mimicking a hormone that regulates appetite, blood sugar, and a host of cardiometabolic factors. When the medication is withdrawn, these benefits begin to reverse. Appetite returns, often more intensely than before, leading to weight regain. Studies show patients can regain up to two-thirds of their lost weight within a year of stopping. This is accompanied by a reversal of improvements in blood pressure, cholesterol, and blood sugar levels, which can return to pre-treatment levels in about a year. This metabolic 'whiplash' appears to be detrimental to long-term heart health.
Why Patients Stop Treatment
Given the clear benefits, why do so many people stop taking these drugs? Discontinuation rates are high, with some estimates suggesting 20% to 50% of patients stop within the first year. The reasons are multifaceted. Persistent gastrointestinal side effects, such as nausea and digestive upset, are a common factor. The high cost and inconsistent availability or shortages of the medication also force many to quit. Others may reach their target weight and believe the treatment is no longer necessary, underestimating the chronic nature of obesity and diabetes. Experts note that illness can also prompt people to stop, which could contribute to the higher risk seen in studies.
More Than Just Weight Regain
The consequences of stopping GLP-1s extend far beyond the numbers on a scale. The reversal of cardiometabolic improvements is a key driver of the heightened risk. For patients with Type 2 diabetes, blood sugar control can worsen, and for those with prediabetes, the risk of developing full-blown diabetes returns. The protective effects on blood pressure and cholesterol also fade, re-exposing the cardiovascular system to the very risks the medication was helping to manage. Some research also points to a potential loss of lean muscle mass during treatment that may not be fully regained, altering body composition for the worse.
A Medically Supervised Decision
The consensus among medical experts is that GLP-1s are intended for long-term management of chronic conditions, not as a short-term fix. The decision to discontinue treatment should never be made abruptly or without a doctor's guidance. While there are no universal tapering protocols yet, a structured plan is crucial. This involves a conversation with a healthcare provider to weigh the risks and benefits and to establish a robust lifestyle plan focusing on diet and exercise to mitigate the rebound effect. The goal is to preserve the health gains achieved during treatment and ensure a safe transition, treating discontinuation as a critical clinical phase rather than an endpoint.
















